| 1420 |
National Cancer Institute |
Html |
en |
Prostate Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. |
| hereditary prostate cancer | 0.542395 |
| prostate biopsy | 0.533126 |
| dutasteride group vs | 0.459041 |
| skin cancer | 0.446356 |
| prostate cancer period | 0.528407 |
| cancer mortality rates | 0.459369 |
| prostate volume subgroups | 0.508967 |
| Prostate Cancer Events | 0.558338 |
| finasteride group versus | 0.448086 |
| rat ventral prostate | 0.516053 |
| high-grade tumors | 0.479135 |
| high-grade cancer | 0.454168 |
| prostate cancer-specific mortality | 0.525559 |
| occult prostate cancer | 0.561891 |
| high-grade prostate cancer | 0.548137 |
| prostate preventive effects | 0.507979 |
| relative risk reduction | 0.446967 |
| radical prostatectomy | 0.460894 |
| prostate cancer mortality | 0.534065 |
| prostate cancer chemoprevention | 0.531007 |
| dietary fat | 0.445789 |
| men | 0.4492 |
| Cancer Events trial | 0.451937 |
| negative prostate biopsy | 0.515564 |
|
| digital rectal examination | 0.454846 |
| dutasteride group | 0.460003 |
| fat intake | 0.450377 |
| Cancer Prevention Trial | 0.500983 |
| prostate digital | 0.500034 |
| prostate cancer risk | 0.564597 |
| placebo group | 0.469544 |
| incident prostate cancer | 0.532469 |
| Cancer Events study | 0.447937 |
| prostate volume | 0.517049 |
| absolute risk reduction | 0.495169 |
| low biologic risk | 0.447169 |
| finasteride group | 0.448145 |
| prostate cancer | 0.910772 |
| Gleason | 0.458954 |
| clinical prostate cancer | 0.556069 |
| pancake-appearing prostate | 0.508749 |
| Prostate Cancer Prevention | 0.595277 |
| prostate cancer. | 0.505972 |
| prostate cancer death. | 0.562581 |
| statistically significant difference | 0.470146 |
| prostate cancers | 0.559985 |
| human prostate cancer | 0.538634 |
|
CLICK HERE |
| 1458 |
National Cancer Institute |
Html |
en |
Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Patient Version |
Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking. |
| cancer treatment | 0.511187 |
| cancer prevention trials | 0.526349 |
| prevention clinical trials | 0.527895 |
| protective factors | 0.503231 |
| new cancers | 0.484789 |
| nicotine withdrawal symptoms | 0.507568 |
| PDQ cancer information | 0.671083 |
| lung cancer | 0.635933 |
| Lung Health Study | 0.490849 |
| clinical trials | 0.665449 |
| cancer information summary | 0.600276 |
| health care professionals | 0.488661 |
| clinical trial | 0.538396 |
| breast cancer prevention | 0.507807 |
| PDQ summaries | 0.484382 |
| Childhood cancer survivors | 0.595809 |
| smoking reduction | 0.509721 |
| cancer risk factor | 0.545024 |
| NCI’s PDQ | 0.484019 |
| NCI PDQ cancer | 0.553403 |
| health problems | 0.510567 |
| cancer recurrence | 0.485421 |
| nicotine replacement products | 0.747838 |
| nicotine replacement product | 0.508467 |
|
| Cancer prevention | 0.618116 |
| cancer protective factor | 0.526183 |
| smokers | 0.498248 |
| Cancer Information Service | 0.517443 |
| smoking | 0.827105 |
| Prevention Editorial Board | 0.530978 |
| treatment clinical trials | 0.488401 |
| National Cancer Institute | 0.611044 |
| cancer death | 0.488965 |
| health care | 0.546707 |
| new treatment | 0.493726 |
| PDQ Cigarette Smoking | 0.572693 |
| Cancer Care page | 0.508742 |
| PDQ database | 0.482266 |
| health | 0.549208 |
| childhood cancer survivor | 0.513387 |
| people | 0.5314 |
| PDQ summary | 0.514038 |
| nicotine gum | 0.499264 |
| cancer clinical trials | 0.526839 |
| risk factors | 0.570886 |
| Public Health Service | 0.486542 |
| cancer information summaries | 0.523287 |
| comprehensive cancer information | 0.523579 |
|
CLICK HERE |
| 1555 |
National Cancer Institute |
Html |
en |
Chronic Myelogenous Leukemia Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia. |
| red blood cells | 0.704307 |
| cancer treatment | 0.518767 |
| blast cells | 0.52224 |
| blast cells increases | 0.484236 |
| following PDQ summaries | 0.473092 |
| PDQ cancer information | 0.548139 |
| clinical trial search | 0.530856 |
| bone marrow disease | 0.473382 |
| white blood cells | 0.672062 |
| donor stem cell | 0.54478 |
| clinical trials | 0.856546 |
| mature blood cells | 0.534844 |
| cancer information summary | 0.513437 |
| clinical trial | 0.70787 |
| stem cell transplant | 0.622548 |
| patients | 0.481704 |
| blood cells | 0.749352 |
| chronic myelogenous leukemia | 0.997869 |
| immature cells | 0.473394 |
| treatment clinical trial | 0.482118 |
| NCI PDQ cancer | 0.480305 |
| Treatment Editorial Board | 0.48584 |
| tyrosine kinase inhibitor | 0.593512 |
| treatment | 0.640788 |
| myeloid stem cell | 0.492405 |
|
| stored stem cells | 0.491127 |
| immature blood cells | 0.498369 |
| blood stem cell | 0.484429 |
| tyrosine kinase | 0.602514 |
| NCI-supported cancer | 0.478389 |
| cancer cells | 0.519678 |
| lymphoid stem cell | 0.493179 |
| specific cancer cells | 0.502587 |
| tyrosine kinase inhibitors | 0.484134 |
| stem cell | 0.637917 |
| treatment clinical trials | 0.506841 |
| blood stem cells | 0.543194 |
| National Cancer Institute | 0.512761 |
| healthy white blood | 0.495783 |
| new treatment | 0.554317 |
| white blood cell | 0.525778 |
| chronic granulocytic leukemia | 0.476374 |
| bone marrow | 0.760079 |
| blastic phase | 0.485946 |
| cancer clinical trials | 0.539698 |
| cancer | 0.652333 |
| information | 0.55566 |
| Myelogenous Leukemia Treatment | 0.486009 |
| standard treatment | 0.485468 |
|
CLICK HERE |
| 1618 |
National Cancer Institute |
Html |
en |
Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version |
The treatment of cancer may cause health problems (late effects) for childhood cancer survivors months or years after successful treatment has ended. Get information about the long-term physical, psychological and social effects of treatment for childhood cancer in this expert-reviewed summary. |
| childhood cancers | 0.431043 |
| cancer treatment | 0.371211 |
| body | 0.373967 |
| childhood cancer survivors | 0.770496 |
| chemotherapy | 0.372336 |
| PDQ cancer information | 0.35879 |
| total-body irradiation | 0.354372 |
| ovarian late effects | 0.364333 |
| bile duct | 0.348106 |
| talk | 0.386582 |
| chest radiation treatment | 0.353115 |
| kidney late effects | 0.373747 |
| joint late effects | 0.365129 |
| cancer information summary | 0.349224 |
| stem cell transplant | 0.480939 |
| pancreatic late effects | 0.367016 |
| heart | 0.364096 |
| symptoms | 0.373794 |
| health problems | 0.529948 |
| tests | 0.430651 |
| primary cancer diagnosis | 0.352818 |
| radiation therapy | 0.438948 |
| following | 0.347799 |
| hormone replacement therapy | 0.348511 |
|
| late effects | 0.94258 |
| treatment | 0.571093 |
| blood vessel | 0.385075 |
| primary cancer | 0.359907 |
| signs | 0.42599 |
| related health problems | 0.511763 |
| procedures | 0.374731 |
| National Cancer Institute | 0.350345 |
| spinal cord | 0.453656 |
| disease | 0.351393 |
| breast cancer risk | 0.350432 |
| breast cancer | 0.372761 |
| brain tumor | 0.349819 |
| thyroid late effects | 0.395111 |
| brain | 0.380353 |
| doctor | 0.354325 |
| radiation treatment | 0.379126 |
| radiation | 0.476283 |
| acute lymphoblastic leukemia | 0.349699 |
| health habits | 0.363956 |
| neuroendocrine late effects | 0.359016 |
| high blood pressure | 0.347712 |
| nonmelanoma skin cancer | 0.356812 |
| lung late effects | 0.390136 |
|
CLICK HERE |
| 1649 |
National Cancer Institute |
Html |
en |
Aromatherapy and Essential Oils (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of aromatherapy and essential oils to improve the quality of life of cancer patients. |
| PDQ Aromatherapy | 0.51751 |
| cancer treatment | 0.518478 |
| modern aromatherapy | 0.502296 |
| certain essential oils | 0.545828 |
| aromatherapy training | 0.496531 |
| PDQ cancer information | 0.582174 |
| Cancer Complementary | 0.49782 |
| hormone -like effects | 0.496783 |
| clinical trials | 0.646919 |
| cancer information summary | 0.54045 |
| aromatherapy massage | 0.496545 |
| alternative cancer therapies | 0.488792 |
| clinical trial | 0.515897 |
| CAM cancer research | 0.479249 |
| patients | 0.520207 |
| cancer patients | 0.499565 |
| Aromatherapy products | 0.529674 |
| bergamot essential oil | 0.494855 |
| literature discuss aromatherapy | 0.518185 |
| NCI PDQ cancer | 0.50787 |
| cancer information database | 0.486869 |
| aromatherapy | 0.710126 |
| international aromatherapy programs | 0.515466 |
| Therapies Editorial Board | 0.490712 |
|
| essential oils | 0.964677 |
| cancer information | 0.591001 |
| treatment | 0.540034 |
| Complementary Therapies Editorial | 0.514222 |
| Drug Administration | 0.547203 |
| Cancer Information Specialist | 0.481775 |
| Aromatherapy research | 0.515581 |
| tree essential oils | 0.64448 |
| Cancer Information Service | 0.537651 |
| tree essential oil | 0.496279 |
| Antibacterial essential oils | 0.531896 |
| National Cancer Institute | 0.639762 |
| alternative medicine | 0.561892 |
| standard aromatherapy certification | 0.518782 |
| term aromatherapy | 0.502247 |
| orange essential oil | 0.494346 |
| aromatherapy courses | 0.496618 |
| tea tree | 0.549957 |
| cancer clinical trials | 0.48888 |
| alternative therapies | 0.505894 |
| ginger essential oil | 0.493305 |
| cancer information summaries | 0.487611 |
| cancer | 0.667969 |
| Holistic Aromatherapy | 0.506338 |
|
CLICK HERE |
| 2015 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de pulmón (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| cigarrillo encendido | 0.533546 |
| voluntarios sanos | 0.521783 |
| secciones llamadas lóbulos | 0.564444 |
| factor protector | 0.54356 |
| rayos x | 0.525531 |
| rayos gamma | 0.526755 |
| altas cantidades | 0.523911 |
| vÃas respiratorias | 0.534485 |
| suplementos vitamina | 0.527073 |
| membrana delgada llamada | 0.563077 |
| National Cancer Institute | 0.526876 |
| Más personas | 0.538369 |
| Instituto Nacional | 0.548081 |
|
| antecedentes familiares | 0.770813 |
| siguientes factores | 0.598507 |
| Physician Data Query | 0.601335 |
| gas radón | 0.544843 |
| prevención revisa | 0.523285 |
| PDQ Prevención | 0.542908 |
| siguientes sustancias | 0.533013 |
| Menor exposición | 0.544963 |
| órganos respiratorios | 0.535883 |
| principal causa | 0.53309 |
| factores protectores | 0.947087 |
| siguientes sumarios | 0.567797 |
| suplementos alimenticios | 0.525893 |
|
CLICK HERE |
| 2037 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de piel (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| skin cancer | 0.991265 |
| cutaneous melanoma | 0.469757 |
| Lippincott Williams | 0.41932 |
| skin cancer prevention | 0.612003 |
| prevent skin | 0.440602 |
| protectores solares | 0.469609 |
| Williams GM | 0.418343 |
| queratosis solares | 0.585992 |
| Sin embargo | 0.685934 |
| protector solar | 0.843096 |
| American Cancer Society | 0.553421 |
| Prev Med | 0.458565 |
| cancer prevention study | 0.448174 |
| case-control study | 0.424296 |
| Study Group | 0.427125 |
| DeVita VT Jr | 0.43478 |
| risk factors | 0.435855 |
| with nonmelanoma skin | 0.42056 |
| isotretinoin-basal cell carcinomas | 0.418488 |
| randomized trial | 0.462527 |
| exposición solar | 0.710997 |
| Natl Cancer Inst | 0.487884 |
| 8th ed | 0.41947 |
| protección solar | 0.624745 |
| melanoma risk factors | 0.418328 |
|
| pruebas insuficientes | 0.419855 |
| Nambour Skin Cancer | 0.466485 |
| cell carcinomas | 0.512878 |
| Halliday GM | 0.422507 |
| Arch Dermatol | 0.425176 |
| Wilson LD | 0.417928 |
| Cancer Facts | 0.43005 |
| Aasi SZ | 0.421096 |
| nevos melanocÃticos benignos | 0.418665 |
| protector solar ayuda | 0.422241 |
| controlled trial | 0.45893 |
| protector solar versus | 0.425736 |
| Epidemiol Biomarkers Prev | 0.463973 |
| exposición solar aguda | 0.467654 |
| Cancer Prevention Trial | 0.454925 |
| Thomas VD | 0.418204 |
| Reduce Actinic Cancer | 0.419285 |
| radiación uv | 0.425436 |
| randomized controlled trial | 0.440826 |
| radiación solar | 0.432514 |
| crema base | 0.420169 |
| nonmelanoma skin cancer | 0.715174 |
| radiación ultravioleta | 0.572893 |
| Cancer Study Group | 0.420229 |
|
CLICK HERE |
| 2072 |
National Cancer Institute |
Html |
es |
Teléfonos celulares y el riesgo de cáncer |
Hoja informativa que resume la evidencia disponible acerca del uso de los teléfonos celulares y el riesgo de cáncer. |
| CERENAT case-control study | 0.411745 |
| multicenter case-control study | 0.411414 |
| epidemiological study results | 0.41093 |
| rayos x | 0.411877 |
| brain glucose metabolism | 0.429587 |
| case-control study | 0.426606 |
| único efecto | 0.412309 |
| tumores benignos | 0.415961 |
| GSM mobile | 0.415087 |
| incidence trends | 0.411018 |
| Ningún estudio | 0.417181 |
| y el riesgo | 0.411067 |
| estudio cerecat | 0.417392 |
| nationwide cohort study | 0.411491 |
| estudio cefalo | 0.417908 |
| NCI evaluó la incidencia | 0.412387 |
| Schüz J | 0.443349 |
| posibles efectos | 0.437506 |
| Estudio Danés | 0.41724 |
| Estados Unidos | 0.572662 |
| teléfonos análogos | 0.439875 |
| teléfonos celulares. TodavÃa | 0.442397 |
| PubMed Abstract | 0.994162 |
| ambicioso estudio | 0.416033 |
| menor riesgo | 0.411527 |
|
| Danish cohort study | 0.411708 |
| mobile phone | 0.603266 |
| International Agency | 0.410998 |
| cerebral blood flow | 0.418576 |
| Johansen C | 0.418262 |
| International Journal | 0.433338 |
| malignant brain tumours | 0.413167 |
| estudio conjunto | 0.41602 |
| cohort study | 0.416338 |
| Deltour I | 0.41865 |
| British Medical Journal | 0.421146 |
| brain neoplasms | 0.419629 |
| brain tumor risk | 0.416486 |
| brain tumours | 0.444382 |
| teléfonos celulares y tumores | 0.450845 |
| participantes controles | 0.41861 |
| international case-control study | 0.411613 |
| sistema nervioso central | 0.469236 |
| brain tumor | 0.443081 |
| cerebro quizás | 0.419107 |
| Cancer Institute | 0.432735 |
| teléfonos celulares causa | 0.474528 |
| pequeños estudios | 0.411116 |
| teléfonos celulares análogos | 0.479549 |
|
CLICK HERE |
| 3581 |
National Cancer Institute |
Html |
en |
Cancer Screening and Early Detection Research |
Information about cancer screening and early detection research, including a summary of NCI programs dedicated to advancing screening and early detection. |
| new screening test | 0.540118 |
| cancer deaths | 0.410053 |
| NCI family studies | 0.383067 |
| lung cancer | 0.420741 |
| Breast Cancer Surveillance | 0.38723 |
| regular screening | 0.445893 |
| colorectal cancer screening | 0.603772 |
| early detection | 0.939503 |
| certain cancers | 0.363738 |
| nonhereditary cancers | 0.350447 |
| cancer diagnosis | 0.409297 |
| Early Detection Research | 0.39067 |
| Colorectal Cancer Outreach | 0.419418 |
| invasive diagnostic tests | 0.349791 |
| cervical cancer | 0.470854 |
| Reduce Cancer Health | 0.403575 |
| follow-up screening | 0.454414 |
| population groups | 0.405687 |
| cancers | 0.545666 |
| effective screening tests | 0.700094 |
| cancer screening | 0.952427 |
| esophageal cancer | 0.349174 |
| cancer prevention | 0.403966 |
| cancer screening practices | 0.592194 |
| United States | 0.470337 |
|
| screening tests | 0.828502 |
| early detection tests | 0.394525 |
| Cancer Treatment | 0.361701 |
| cancer cells | 0.354406 |
| new screening tests | 0.532154 |
| successful screening approach | 0.50247 |
| annual screening | 0.507755 |
| screening clinical trials | 0.513432 |
| National Lung Screening | 0.514111 |
| breast cancer screening | 0.628104 |
| potentially lethal cancers | 0.414445 |
| advanced cancer | 0.354994 |
| Research Optimizing Screening | 0.517143 |
| screen-detected cancers | 0.368122 |
| cancer screening tests | 0.606127 |
| CT-based screening | 0.448353 |
| hereditary cancers | 0.34998 |
| lung cancer risk | 0.409654 |
| false-positive screening tests | 0.535547 |
| Screening Initiative | 0.447841 |
| cancer mortality | 0.418544 |
| screening methods | 0.487692 |
| Cancer Screening Trial | 0.590657 |
| life-threatening cancers | 0.360993 |
|
CLICK HERE |
| 16374 |
National Cancer Institute |
Html |
en |
Cancer Moonshot℠ – Funding Opportunities |
NCI is accepting applications for research grants that support the Cancer Moonshot Blue Ribbon Panel recommendations to accelerate cancer research. |
| Cancer Drug Resistance | 0.295868 |
| Science Network Cancer | 0.308038 |
| Human Tumor Atlases | 0.404045 |
| Immunotherapy Translational Science | 0.984441 |
| Science Accelerating Colorectal | 0.287912 |
| Fusion Oncoproteins | 0.307628 |
| Cancer Immunoprevention Research | 0.286973 |
| Cancer Immunotherapy Translational | 0.970237 |
| Network Pediatric Immunotherapy | 0.362271 |
| Pediatric Immunotherapy Discovery | 0.349074 |
| Tumor Atlases Human | 0.296142 |
| Implementation Science Improving | 0.29186 |
| Translational Science Network | 0.875874 |
| Management Research Research | 0.283205 |
| New Enabling Technologies | 0.348633 |
| Network Metabolic Reprogramming | 0.28898 |
| Immuno-Oncology Translation Network | 0.34437 |
| Promote Research Collaborations | 0.285621 |
| Science Improving Smoking | 0.284218 |
| Colorectal Cancer Screening | 0.294277 |
| Research Projects | 0.27874 |
| Cancer Data Ecosystem | 0.284367 |
| Science Network Metabolic | 0.302007 |
| Cancer Moonshot | 0.286234 |
| Network Canine Immunotherapy | 0.334919 |
|
| Implementation Science Accelerating | 0.293234 |
| PHS2018-1/ Topic | 0.305631 |
| Research Centers | 0.280481 |
| Network Immuno-Oncology Translation | 0.344385 |
| Cancer Immunotherapy Research | 0.375931 |
| Symptom Management Research | 0.365508 |
| Childhood Cancers | 0.296073 |
| Science Network Research | 0.294604 |
| Early Detection | 0.350699 |
| Accelerating Colorectal Cancer | 0.296449 |
| National Cancer Data | 0.285248 |
| Science Network Coordinating | 0.277495 |
| Network Cancer Immunologic | 0.279507 |
| Canine Immunotherapy Trials | 0.339278 |
| Network Cancer Immune | 0.278836 |
| Translational Studies | 0.295595 |
| Human Tumor Atlas | 0.288789 |
| Translational Research | 0.303812 |
| Cancer Moonshot-related activities | 0.277278 |
| Immunotherapy Data Resource | 0.338479 |
| Atlases Human Tumor | 0.296132 |
| Science Network Pediatric | 0.294096 |
| Science Network Immuno-Oncology | 0.350197 |
| Implementation Science | 0.370631 |
|
CLICK HERE |